

## HIV Resistance and Ibalizumab

**Date:** 8/28/2018

**Time:** 12:00 – 1:00 PM

Continuing Pharmacy Education Program  
Clinical Pharmacy Associates, Inc. &  
DC Department of Health

**Who should attend:** The program is designed for pharmacists in the DC HIV/AIDS Pharmacy Network and pharmacists in client organizations of CPA/MedNovations.

**Needs Statement:** HIV resistance and the novel, monoclonal antibody ibalizumab must be understood and properly utilized by pharmacists in the pharmaceutical care of PLWH.

**Statement of Goal:** To equip practicing pharmacists with current knowledge and skill to utilize ibalizumab safely and efficaciously in the care of HIV resistant populations.

**Activity Type:** Knowledge

**Objectives:** After completing the program, participants should be able to:

1. Explain resistance mechanisms between different classes of antiretrovirals
2. Describe the pharmacotherapy of ibalizumab-uiyk
3. Describe the subpopulation of HIV patients in which ibalizumab-uiyk would be utilized

### **Faculty**

**Susie H. Park, Pharm.D.**

Infectious Disease Fellowship  
Loma Linda Univ. Medical Center  
Loma Linda, CA

**Fee:** N/A



®Howard University College of Pharmacy, (HUCOP)-Office of Continuing Professional Education (CPE) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. **This program meets ACPE criteria for one contact hour (0.1 CEU).** Credit will be awarded through the CPE Monitor, within 3–4 weeks of the seminar to those who successfully complete the program. Using the following URL: <https://hurxce.learningexpressce.com/index.cfm>, the evaluation form and a score  $\geq 70\%$  correct on post-test questions will be required for successful completion. The ACPE Universal Program number assigned to this program is **0010-9999-18-009-L02-P**